• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

层粘连蛋白-332 缺乏型非赫勒氏交界型先天性大疱性表皮松解症患者慢性溃疡的打孔移植。

Punch grafting of chronic ulcers in patients with laminin-332-deficient, non-Herlitz junctional epidermolysis bullosa.

机构信息

Department of Dermatology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.

出版信息

J Am Acad Dermatol. 2013 Jan;68(1):93-7, 97.e1-2. doi: 10.1016/j.jaad.2012.04.012. Epub 2012 May 26.

DOI:10.1016/j.jaad.2012.04.012
PMID:22633040
Abstract

BACKGROUND

Epidermolysis bullosa (EB) is a genetic, heterogeneous, trauma-induced blistering disease. Patients with laminin-332-deficient non-Herlitz junctional EB (JEB-nH) can have impaired wound healing witnessed by persistent, small, deep ulcers on the hands and feet that adversely affect the quality of life.

OBJECTIVE

We sought to present the results of punch grafting in patients with laminin-332-deficient JEB-nH, and to discuss its therapeutic value.

METHODS

Retrospective analysis of the Dutch EB Registry revealed 4 patients with laminin-332-deficient JEB-nH who were treated with punch grafting. Punch grafting was performed according to protocol, and the patients were followed up.

RESULTS

In the past 10 years we have treated 23 ulcers in 4 patients with JEB-nH using punch grafting without any complications or adverse effects. The ulcers had on average persisted 6 years before treatment. Healing rate after punch grafting was 70% (n = 16), with a mean healing time of 2 months. Thirty percent (n = 7) of the treated ulcers did not completely heal, but did show improvement. The recurrence rate after 3 months was 13% (n = 2), and was a result of renewed blistering.

LIMITATIONS

Limitations of the study are the retrospective design, small number of patients, absence of a control group, and follow-up and ulcer measurement that were not standardized.

CONCLUSIONS

Punch grafting can be used as a first-line treatment in small persistent ulcers in patients with JEB-nH. The method is easy, is inexpensive, has little risk of complications, and results in significant healing rates and improvement in quality of life.

摘要

背景

大疱性表皮松解症(EB)是一种遗传性、异质性、创伤诱导性的水疱性疾病。层粘连蛋白 332 缺陷型非交界性大疱性表皮松解症(JEB-nH)患者由于手部和足部持续存在小而深的溃疡,伤口愈合能力受损,这会对生活质量产生不利影响。

目的

我们旨在介绍层粘连蛋白 332 缺陷型 JEB-nH 患者接受打孔移植术的结果,并讨论其治疗价值。

方法

对荷兰 EB 注册处进行回顾性分析,发现 4 例层粘连蛋白 332 缺陷型 JEB-nH 患者接受了打孔移植术治疗。根据方案进行打孔移植术,对患者进行随访。

结果

在过去 10 年中,我们使用打孔移植术治疗了 4 例 JEB-nH 患者的 23 处溃疡,没有任何并发症或不良反应。这些溃疡在接受治疗前平均持续了 6 年。打孔移植术后的愈合率为 70%(n=16),平均愈合时间为 2 个月。30%(n=7)的治疗溃疡未完全愈合,但有所改善。3 个月后的复发率为 13%(n=2),这是由于重新出现水疱。

局限性

本研究的局限性在于回顾性设计、患者数量少、缺乏对照组以及随访和溃疡测量未标准化。

结论

打孔移植术可作为 JEB-nH 患者小面积持续性溃疡的一线治疗方法。该方法简单、经济、并发症风险低,愈合率高,生活质量显著改善。

相似文献

1
Punch grafting of chronic ulcers in patients with laminin-332-deficient, non-Herlitz junctional epidermolysis bullosa.层粘连蛋白-332 缺乏型非赫勒氏交界型先天性大疱性表皮松解症患者慢性溃疡的打孔移植。
J Am Acad Dermatol. 2013 Jan;68(1):93-7, 97.e1-2. doi: 10.1016/j.jaad.2012.04.012. Epub 2012 May 26.
2
Epidemiology of epidermolysis bullosa in the antipodes: the Australasian Epidermolysis Bullosa Registry with a focus on Herlitz junctional epidermolysis bullosa.澳大拉西亚地区大疱性表皮松解症的流行病学:以澳大利亚大疱性表皮松解症登记处为重点,聚焦于赫利茨交界型大疱性表皮松解症。
Arch Dermatol. 2010 Jun;146(6):635-40. doi: 10.1001/archdermatol.2010.109.
3
Long-term follow-up of patients with Herlitz-type junctional epidermolysis bullosa.遗传性交界型大疱性表皮松解症患者的长期随访。
Br J Dermatol. 2012 Aug;167(2):374-82. doi: 10.1111/j.1365-2133.2012.10997.x. Epub 2012 Jul 5.
4
Successful therapeutic transplantation of revertant skin in epidermolysis bullosa.成功地对大疱性表皮松解症进行逆转录皮肤的治疗性移植。
J Am Acad Dermatol. 2014 Jan;70(1):98-101. doi: 10.1016/j.jaad.2013.08.052. Epub 2013 Oct 29.
5
Keratinocytes from junctional epidermolysis bullosa do adhere and migrate on the basement membrane protein nicein through alpha 3 beta 1 integrin.交界型大疱性表皮松解症的角质形成细胞通过α3β1整合素确实能在基底膜蛋白尼斯因上黏附并迁移。
Lab Invest. 1994 Oct;71(4):567-74.
6
Risk of squamous cell carcinoma in junctional epidermolysis bullosa, non-Herlitz type: report of 7 cases and a review of the literature.交界型大疱性表皮松解症非 Halleritz 型中鳞癌的风险:7 例报告及文献复习。
J Am Acad Dermatol. 2011 Oct;65(4):780-789. doi: 10.1016/j.jaad.2010.07.006. Epub 2011 May 31.
7
Treatment of two patients with Herlitz junctional epidermolysis bullosa with artificial skin bioequivalents.使用人工皮肤生物等效物治疗两名患有赫利茨交界性大疱性表皮松解症的患者。
J Pediatr. 2002 Oct;141(4):553-9. doi: 10.1067/mpd.2002.127794.
8
Cause-specific risks of childhood death in inherited epidermolysis bullosa.遗传性大疱性表皮松解症患儿特定病因的死亡风险
J Pediatr. 2008 Feb;152(2):276-80. doi: 10.1016/j.jpeds.2007.06.039. Epub 2007 Oct 22.
9
[Junctional epidermolysis bullosa non-Herlitz with urethral affection].[非赫利茨型交界性大疱性表皮松解症伴尿道受累]
J Dtsch Dermatol Ges. 2003 Jan;1(1):50-6.
10
Herlitz junctional epidermolysis bullosa: diagnostic features, mutational profile, incidence and population carrier frequency in the Netherlands.遗传性交界型大疱性表皮松解症:荷兰的诊断特征、突变特征、发病率和人群携带者频率。
Br J Dermatol. 2011 Dec;165(6):1314-22. doi: 10.1111/j.1365-2133.2011.10553.x. Epub 2011 Nov 17.

引用本文的文献

1
Skin Micro-Fragments for the Management of Diabetic Foot Ulcers: A Case Series.用于治疗糖尿病足溃疡的皮肤微碎片:病例系列
Int J Low Extrem Wounds. 2025 Mar;24(1):51-58. doi: 10.1177/15347346241311046. Epub 2025 Jan 8.
2
Immune tolerance of allogeneic haematopoietic cell transplantation supports donor epidermal grafting of recessive dystrophic epidermolysis bullosa chronic wounds.异基因造血细胞移植的免疫耐受支持隐性营养不良性大疱性表皮松解症慢性伤口的供体表皮移植。
Br J Dermatol. 2021 Jun;184(6):1161-1169. doi: 10.1111/bjd.19503. Epub 2020 Dec 14.
3
Molecular Therapeutics in Development for Epidermolysis Bullosa: Update 2020.
正在开发中的用于大疱性表皮松解症的分子疗法:2020 年更新。
Mol Diagn Ther. 2020 Jun;24(3):299-309. doi: 10.1007/s40291-020-00466-7.
4
Leading edge: emerging drug, cell, and gene therapies for junctional epidermolysis bullosa.前沿:用于交界型大疱性表皮松解症的新兴药物、细胞和基因疗法。
Expert Opin Biol Ther. 2020 Aug;20(8):911-923. doi: 10.1080/14712598.2020.1740678. Epub 2020 Mar 20.
5
Novel and emerging therapies in the treatment of recessive dystrophic epidermolysis bullosa.隐性营养不良性大疱性表皮松解症治疗中的新型及新兴疗法。
Intractable Rare Dis Res. 2017 Feb;6(1):6-20. doi: 10.5582/irdr.2017.01005.